Abeona Therapeutics Inc Cash Flow Conversion Efficiency
Abeona Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Abeona Therapeutics Inc (ABEO) has a cash flow conversion efficiency ratio of -0.137x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.50 Million) by net assets ($128.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Abeona Therapeutics Inc (1995–2025)
Cash flow conversion efficiency of Abeona Therapeutics Inc from 1995 to 2025. This chart illustrates how Abeona Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ABEO live share price for real-time trading data and today's change.
Abeona Therapeutics Inc Cash Flow Conversion Ratio Explained
Abeona Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Abeona Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abeona Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Abeona Therapeutics Inc (ABEO) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Range Capital Acquisition Corp II Class A Ordinary Shares
NASDAQ:RNGT
|
0.000x |
|
Perma-Pipe International Holdings Inc
NASDAQ:PPIH
|
0.065x |
|
Arqit Quantum Inc.
NASDAQ:ARQQ
|
-0.886x |
|
Langfang Development Co Ltd
SHG:600149
|
-0.013x |
|
ProCap Financial, Inc.
NASDAQ:BRR
|
-0.043x |
|
NEXCOM International Co Ltd
TWO:8234
|
0.017x |
|
Accel S.A.B. de C.V
MX:ACCELSAB
|
-0.112x |
|
Jih Lin Technology Co Ltd
TW:5285
|
0.010x |
Annual Cash Flow Conversion Efficiency for Abeona Therapeutics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Abeona Therapeutics Inc from 1995 to 2025. Review Abeona Therapeutics Inc (ABEO) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $159.22 Million | $-76.33 Million | -0.479x | +62.32% |
| 2024-12-31 | $44.03 Million | $-56.02 Million | -1.272x | +49.04% |
| 2023-12-31 | $14.83 Million | $-37.01 Million | -2.496x | -53.63% |
| 2022-12-31 | $26.76 Million | $-43.48 Million | -1.625x | -4.84% |
| 2021-12-31 | $42.37 Million | $-65.67 Million | -1.550x | -353.87% |
| 2020-12-31 | $102.55 Million | $-35.02 Million | -0.341x | +3.01% |
| 2019-12-31 | $178.43 Million | $-62.82 Million | -0.352x | -20.67% |
| 2018-12-31 | $134.04 Million | $-39.11 Million | -0.292x | -116.40% |
| 2017-12-31 | $170.10 Million | $-22.93 Million | -0.135x | -2.67% |
| 2016-12-31 | $99.10 Million | $-13.01 Million | -0.131x | +14.67% |
| 2015-12-31 | $67.72 Million | $-10.42 Million | -0.154x | +53.99% |
| 2014-12-31 | $4.82 Million | $-1.61 Million | -0.335x | -494272.28% |
| 2013-12-31 | $-14.78 Million | $1.00K | 0.000x | -100.03% |
| 2012-12-31 | $-17.08 Million | $-3.96 Million | 0.232x | -46.41% |
| 2011-12-31 | $-17.61 Million | $-7.61 Million | 0.432x | +31.01% |
| 2010-12-31 | $-20.80 Million | $-6.86 Million | 0.330x | +296.06% |
| 2009-12-31 | $-26.99 Million | $-2.25 Million | 0.083x | -85.80% |
| 2008-12-31 | $-11.19 Million | $-6.56 Million | 0.586x | -91.75% |
| 2007-12-31 | $681.00K | $4.84 Million | 7.112x | +3491.03% |
| 2006-12-31 | $-9.89 Million | $-1.96 Million | 0.198x | -88.51% |
| 2005-12-31 | $-4.24 Million | $-7.30 Million | 1.723x | +26.45% |
| 2004-12-31 | $-6.66 Million | $-9.08 Million | 1.363x | +24.75% |
| 2003-12-31 | $-5.83 Million | $-6.36 Million | 1.092x | +106.21% |
| 2002-12-31 | $489.00K | $-8.60 Million | -17.577x | -2926.58% |
| 2001-12-31 | $9.08 Million | $-5.27 Million | -0.581x | -101.19% |
| 2000-12-31 | $15.00 Million | $-4.33 Million | -0.289x | +67.98% |
| 1999-12-31 | $3.60 Million | $-3.25 Million | -0.901x | +49.30% |
| 1998-12-31 | $1.80 Million | $-3.20 Million | -1.778x | +70.65% |
| 1997-12-31 | $599.00K | $-3.63 Million | -6.057x | -821.68% |
| 1996-12-31 | $4.06 Million | $-2.67 Million | -0.657x | -268.38% |
| 1995-12-31 | $1.69 Million | $658.00K | 0.390x | -- |
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more